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A B S T R A C T
In last two decades there was a huge step forward concerning rectal cancer treatment. The aim of our study was com-
parison of two time intervals regarding the methods of treatment and results of radical rectal cancer surgery. 407 pa-
tients operated on for rectal cancer were included in study. Those were patients with elective radical resection of solitary
rectal tumor who survived first month after the operation. Patients were divided in two groups regarding the time of op-
eration. In group one were patients operated on between 1996 and 2000 and in group two patients operated on between
2001 and 2005. We compared our results in both intervals with special interest about type of operation considering local-
ization of the tumor, local recurrence and cancer related survival. Significant differences were found between two groups.
There were more sphincter saving operations in second group, less local recurrences and better survival than in first
group. This study observed significant improvements at recurrence rates and total survival for patients operated on rec-
tal cancer.
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Introduction
Rectal cancer has become one of the most frequent
types of cancers among men and women in the majority
of European industrialized countries and represents an
important factor of morbidity and mortality.
Presently, it accounts for one third of all colorectal
carcinomas. In Slovenia during 2004, we diagnosed 582
patients with carcinoma of the rectum and rectosigmoid
colon1.
Despite all progress in the development of conserva-
tive therapy (i.e., radiation and chemotherapy), radical
surgical removal of the tumor is the only chance of per-
manent cure of the disease. Survival is also directly con-
nected with the stage of the tumor, assessed by indicating
the depth of penetration of the tumor into the bowel wall
(T stage), the extent of lymph node involvement (N
stage), and the presence of distant metastases (M stage).
All those are the major threats for patients afflicted,
leading to locoregional as well as distant recurrences.
The highly disappointing rates of local failure after
curative resection in rectal cancer not only led to the de-
velopment of adjuvant therapies but were also a strong
motor for surgical refinements. Although the importance
of clear distal, proximal, and circumferential margins
and proposals to achieve them were postulated long ago,
it took more than a decade to integrate those principles,
performed as total mesorectal excision (TME), into surgi-
cal routine in curative resections of cancer of the mid and
lower third of the rectum2–7. In the meantime, not only
expert series on the benefits of total mesorectal excision
have been published. It has been stated that surgical
teaching initiative had a major effect on cancer out-
comes. The proportion of abdominoperineal procedures
and the local recurrence rate decreased by more than
50% and there is already evidence of a decline in rec-
tal-cancer mortality. Regional or even nationwide sur-
veys as well have documented a marked decrease of local
recurrences up to 50% and potentially even a survival
benefit8–12.
Adjuvant systemic therapy for rectal and colon cancer
was introduced by a national consensus conference in the
USA in 1990. Shortly thereafter and mainly based on two
rather small trials, the postoperative simultaneous com-
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bination of radiotherapy and chemotherapy became a
standard in most western countries, as a survival benefit
of up to 20–40% seemed achievable by combined modal-
ity treatment13–15. In 1994, continuous application of
5-Fluorouracil (CI) proved to be superior given simulta-
neously to adjuvant radiation. As uncomplicated central
venous access lines nowadays are broadly available and
due to its favorable toxicity profile, CI is an established
standard, although the survival benefit attributed to it
could not be reproduced in the recently published GI INT
0144 study on more than 1,900 patients16–17. A further
change of the strategy was introduced by a large phase-
-III study demonstrating the superiority of preoperative
over postoperative chemoradiation in terms of local re-
currence rates (6 vs. 13%) as well as severe late side ef-
fects (14 vs. 24%). The risk of overtreatment of up to 20%
of the patients due to inadequate preoperative staging in-
herent in this strategy was considered to be acceptable18.
Materials and Methods
From 1996 data of all rectal cancer patients are simul-
taneously registered in specially designed protocols which
contain preoperative, operative and postoperative part
and detailed pathological report. Data of all patients op-
erated on between January 1996 and December 2005
were analyzed. In this period 628 patients with rectal
carcinoma were operated on but only 406 patients were
eligible for study which included patients with elective
radical resection of solitary rectal tumor who survived
first month after the operation.
The ten year period 1996–2005 was divided in two
time intervals. First 5-year interval between 1996–2000
and second interval between years 2001–2005. It was in
the year 2000 when we have started more profound with
TME surgical technique and also with neoadjuvant ther-
apy which had represented in those times mostly short
term preoperative radiotherapy.
We compared our results in both intervals with spe-
cial consideration about the type of operation consider-
ing localization of the tumor, local recurrence and cancer
related survival.
TNM staging system for rectal cancer was used dur-
ing this study. All patients underwent liver ultrasound
and chest radiogram before surgery and border cases
were further examined using a CT scan. Final liver sta-
tus has been confirmed by bimanual intraoperative pal-
pation or even intraoperative ultrasound.
The majority of operations were performed by abdom-
inal surgeons with a special interest in colorectal surgery.
The surgical procedure was termed curative if there
was complete macroscopic removal of the tumor, as con-
B. Krebs et al.: Rectal Cancer Surgery and Survival, Coll. Antropol. 36 (2012) 2: 419–423
420
Local recurrence rate according to group
Complete Censored
0 1 2 3 4 5 6 7



















Fig. 1. Local recurrence rate according to group.


















































Fig. 2. 5 and 10 – year cancer specific survival after curative re-
section for all patients.
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Fig. 3. Difference in 5-year cancer related survival (Kaplan-Mei-
er) between two groups.
firmed by a pathologist, and there were no signs of meta-
static disease. The radicality of the operation was ac-
cessed according to R classification, which was confirmed
in 1987 by UICC.
All patients were followed up on a regular basis ac-
cording to our national recommendation: at 3 month in-
tervals during the first two years, at 6 month intervals
until the5th year, and then annually19. Clinical examina-
tion, tumor markers (CEA and CA19-9) and ultrasound
were performed at each appointment. A chest X-ray was
performed every 6 months during the first two years and
then annually. Colonoscopy was performed once a year
after the operation. Follow up was updated on December
31st 2008.
Recurrence was defined as cancer detected in the pel-
vis regardless of whether some other metastases were
found in other tissues or organs. Isolated local recur-
rence was defined as cancer detected in the pelvis only.
Distant metastases were defined as tumor recurrence
outside the pelvis and included metastases of the liver,
lungs, bones or brain.
Data concerning death was acquired from the Slove-
nian cancer register, and the cause verified for cancer
specificity for each deceased patient20.
Survival was calculated using the Kaplan-Meier me-
thod and compared using the log-rank test. All analyses
were performed using statistical SPSS software for Win-
dows 10.0.
Results
Between 1996 and 2005 we operated on 628 patients
with rectal cancer. The number of patients operated on
fluctuated.
According to our criteria, we included 406 patients in
study, which represented 66 percent of all those operated
on. There were slightly more men (215) than women
(191). The median age of the patients was 66, 9 years
(range 29–93). All patients were divided in two groups.
There were 172 patients who were operated on between
year 1996 and 2000 and 234 patients operated on be-
tween 2001 and 2005. The percentage of eligible patients
is higher in second group of patients (Table 1).
We can see clearly in Table 2 that in the second time
interval there was a significant fall in number of mutilat-
ing operations such as abdominoperineal excisions (APE),
and rise of sphincter preserving low anterior resections
(LAR).
It is obvious that in first period between 1996 and
2000 (group 1) there were a lot of abdominoperineal exci-
sions performed on. The number of those operations
than decreases on account of low anterior resection oper-
ations. The difference is especially obvious at cancers lo-
cated at middle third of rectum (Table 3). While in first
period nearly half of patients with rectal cancer between
7 and 12 centimeters ended with stoma, in second period
this rate falls to only 10 percent.
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TABLE 1
NUMBER OF ALL PATIENTS OPERATED ON FOR RECTAL
CANCER PER YEAR AND PERCENTAGE OF STUDY ELIGIBLE








1996 43 27 62.79
1997 54 36 66.67
1998 78 46 58.97
1999 52 31 59.62




2001 73 51 69.86
2002 58 35 60.34
2003 84 58 69.05
2004 60 45 75.00











Low anterior resection 75 (44%) 153 (66%)
Abdominoperineal excision 88 (51%) 62 (26%)
Low anterior resection with
stoma
5 (3%) 10 (4%)
Other 4 (2%) 9 (4%)
TABLE 3
TYPE OF OPERATION ACCORDING TO GROUP AND DISTANCE OF THE TUMOR FROM ANOCUTANEAL VERGE
Location
of tumor
0–7 cm 7–12 cm 12–15 cm
Group 1 Group2 Group1 Group2 Group1 Group2
N=63 N=98 N=63 N=78 N=46 N=58
Technique
LAR 1 (1.6 %) 33 (34%) 31 (49%) 66 (85%) 43 54
APE 58 (92%) 53 (54 %) 30 (48%) 8 (10%) 0 0
The rate of local recurrence (LR) was 9.11% for all pa-
tients in study. In first group there were 22 local recur-
rences or 12.8% and in second group 15 patients with LR
(6.4%). There was significant difference between both
groups (p<0.005).
Patients in group 2 had better 5-year cancer specific
survival –69% and patients in group 1 only 59% (p<0.005).
Discussion and Conclusion
In the recent 20 years, improvements have been rea-
ched in the outcomes of colorectal surgery with the
better diagnostic and staging methods, advances in sur-
gical techniques as well as adjuvant therapy20,21.
According to our results, there was a significant in-
crease in the number of radical operations. In second pe-
riod the rate of curative resections was 10 percent higher
than five years before. We believe that this is the result of
better preoperative staging, better operative technique
and of course result of positive effect of preoperative
chemoradiotherapy. Many tumors, first valued as non
resectable could have been resected after downsizing and
downgrading effect of oncological therapy.
The results of our study have shown a significant
trend over the ten year period towards the better progno-
sis for patients with rectal cancer.
It is difficult to ascribe improvements demonstrated
in our study to one single factor. More likely they have re-
sulted from a number of changes22. One of them is surely
a shift in operating mode from abdominoperineal exci-
sion towards low anterior resection.
Many studies stated that local recurrence and sur-
vival rates after anterior resection have improved to the
higher degree as that seen with abdominoperineal exci-
sion of the rectum and anus23,24. The difference in out-
come may be explained by a combination of the anatomic
and surgical difficulties associated with standard APE
surgery.
Our results show that in short period we manage to di-
minish the share of APE for nearly 40 percent for patie-
nts with rectal cancer in the middle third of rectum and
this could be an important factor in overall improvement.
Another issue, closely related to operative manage-
ment, is introduction of total mesorectal excision, a tech-
nique which improved the local recurrence control and
survival all over the world25.
In recent years neoadjuvant therapy made a huge
step forward. Nowadays all of our patients with stage 3
and some with stage 2 rectal cancers receive neoadjuvant
therapy which became standard in treatment of rectal
cancer. Together with adjuvant treatment it is indispens-
able in rectal cancer treatment.
The improvements in survival and local recurrence
control may also reflect better quality staging and histo-
logical review. More accurate staging through the detec-
tion of metastases or nodal disease could create a notice-
able improvement in results. Pathologists now have a
standardized reporting procedure and improved staging
can select out poor prognostic patients, leading to appar-
ent stage migration.
In conclusion we can stress that we have observed a
significant improvements in rates of recurrence and in
total survival after rectal cancer operations and we can
say that our results are improving but there is still much
work to do to be able to compare us with the world’s lead-
ing centers for rectal cancer surgery.
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LIJE^ENJE RAKA REKTUMA I STOPA PRE@IVLJAVANJA – USPOREDBA DVA VREMENSKA
INTERVALA OD PET GODINA
S A @ E T A K
U posljednja je dva desetlje}a u~injen velik napredak u lije~enju raka rektuma. Cilj na{eg istra`ivanja bio je uspo-
rediti dva vremenska intervala s obzirom na metode lije~enja i rezultate radikalne rektalne operacije. U studiju je bilo
uklju~eno 407 pacijenata kojima je odstranjen rektalni tumor, a koji su pre`ivjeli prvi mjesec nakon operacije. Pacijenti
su podijeljeni u dvije skupine s obzirom na vrijeme operacije. U jednoj skupini bili su pacijenti operirani izme|u 1996. i
2000. godine, a u drugoj pacijenti operirani izme|u 2001. i 2005. godine. Usporedili smo dobivene rezultate s posebnim
osvrtom na tip operacije i poziciju tumora, ponovno lokalno pojavljivanje tumora i stopu pre`ivljavanja. Uo~ene su
zna~ajne razlike izme|u dvije skupine. U drugoj je skupini bilo vi{e pacijenata kod kojih je operacijom spa{en sfinkter,
kod kojih ima manje slu~aja ponovnog lokalnog pojavljivanja tumora i koji imaju vi{u stopu pre`ivljavanja. Iz na{ih
rezultata mo`emo zaklju~iti da je vidljiv znatan napredak u stopi pre`ivljavanja pacijenata koji boluju od raka rektuma,
no jo{ uvijek nas ~eka mnogo posla dok se ne budemo mogli uspore|ivati s najboljim svjetskim centrima za operativne
zahvate vezane uz rak rektuma.
